Mycophenolate Mofetil plus prednisolone
ApprovedSmall molecule
Mycophenolate Mofetil plus prednisolone is one of 5 small molecule programs targeting Hypersensitivity Pneumonitis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Hypersensitivity Pneumonitis
#DrugCompanyPhaseTrials
1Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Methyl Prednisolonate
UUniversity Hospital Muenster
Approved
Esbriet
LLegacy Health System
Phase 2
Mycophenolate Mofetil plus prednisolone
PPost Graduate Institute of Medical Education and Research, Chandigarh
Approved
Salbutamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypersensitivity Pneumonitis1 trial
An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 4·NCT05626387·144 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details